Nuvectis Pharma, Inc. (NASDAQ: NVCT) announced the pricing of its previously disclosed underwritten public offering of 5 million shares of common stock at $20.00 per share, with expected gross proceeds of approximately $100 million. The offering, which is expected to close on or about July 1, 2026, subject to customary conditions, includes a 30-day option for underwriters to purchase up to an additional 750,000 shares at the same price, less underwriting discounts and commissions. Cantor is serving as the sole book-running manager, with H.C. Wainwright & Co., Laidlaw & Company (UK) Ltd., Lucid Capital Markets, Maxim Group LLC, Roth Capital Partners, and Titan Partners acting as co-managers.
The company stated that the net proceeds will be used to advance development of its NXP100, NXP200, and NXP900 programs, support future product candidates, hire additional personnel, fund capital expenditures, and cover general corporate purposes. This capital infusion comes at a critical time as Nuvectis progresses its pipeline of innovative therapies for immune complement-related conditions and oncology.
Nuvectis' lead candidate, NXP100, is a late-stage Factor B inhibitor with best-in-class potential for multiple complement-mediated diseases. It is designed as the only once-daily oral treatment option for these conditions, which require lifelong therapy. NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases, including SRC and YES1, intended to inhibit both catalytic and scaffolding functions of the SRC kinase, leading to comprehensive shutdown of the signaling pathway. NXP200 is an oral, brain-penetrant, paradox-breaker BRAF inhibitor targeting BRAF V600X-mutated and Class II/III non-V600-mutated solid tumors, including central nervous system cancers, colorectal cancer, melanoma, and non-small cell lung cancer.
The successful pricing of this offering underscores investor confidence in Nuvectis' approach and the potential of its pipeline. With these funds, the company is well-positioned to advance its clinical programs toward key milestones. For more information, visit the company's website at https://nuvectis.com/. The full press release is available at https://ibn.fm/SrZnr.
